AJP - Endo Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 279: E501-E507, 2000;
0193-1849/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heffernan, M. A.
Right arrow Articles by Ng, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heffernan, M. A.
Right arrow Articles by Ng, F. M.
Vol. 279, Issue 3, E501-E507, September 2000

Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism

M. A. Heffernan1, W. J. Jiang1, A. W. Thorburn2, and F. M. Ng1

1 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3148; and 2 Department of Medicine, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia

A small synthetic peptide sequence of human growth hormone (hGH), AOD-9401, has lipolytic and antilipogenic activity similar to that of the intact hormone. Here we report its effect on lipid metabolism in rodent models of obesity and in human adipose tissue to assess its potential as a pharmacological agent for the treatment of human obesity. C57BL/6J (ob/ob) mice were orally treated with either saline (n = 8) or AOD-9401 (n = 10) for 30 days. From day 16 onward, body weight gain in AOD-9401-treated animals was significantly lower than that of saline-treated controls. Food consumption did not differ between the two groups. Analyses of adipose tissue ex vivo revealed that AOD-9401 significantly reduced lipogenic activity and increased lipolytic activity in this tissue. Increased catabolism was also reflected in an acute increase in energy expenditure and glucose and fat oxidation in ob/ob mice treated with AOD-9401. In addition, AOD-9401 increased in vitro lipolytic activity and decreased lipogenic activity in isolated adipose tissue from obese rodents and humans. Together, these findings indicate that oral administration of AOD-9401 alters lipid metabolism in adipose tissue, resulting in a reduction of weight gain in obese animals. The marked lipolytic and antilipogenic actions of AOD-9401 in human adipose tissues suggest that this small synthetic hGH peptide has potential in the treatment of human obesity.

human growth hormone peptide; lipolysis; lipogenesis; energy expenditure


This article has been cited by other articles:


Home page
 J. Nutr.Home page
S. H. Adams, C. Lei, C. M. Jodka, S. E. Nikoulina, J. A. Hoyt, B. Gedulin, C. M. Mack, and E. S. Kendall
PYY[3-36] Administration Decreases the Respiratory Quotient and Reduces Adiposity in Diet-Induced Obese Mice
J. Nutr., January 1, 2006; 136(1): 195 - 201.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Z. Yanovski and J. A. Yanovski
Obesity
N. Engl. J. Med., February 21, 2002; 346(8): 591 - 602.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. E. E. Jones, A. W. Thorburn, K. L. Britt, K. N. Hewitt, N. G. Wreford, J. Proietto, O. K. Oz, B. J. Leury, K. M. Robertson, S. Yao, et al.
Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity
PNAS, November 7, 2000; 97(23): 12735 - 12740.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online